Engineered Gamma Delta T-Cells for Solid Tumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adoptive cellular therapy approaches for solid tumors face challenges in specificity, safety, and efficacy, particularly with γδ T cells due to unclear co-stimulation requirements and the risk of graft-versus-host effects, and inefficacy in solid tissues and inhibitory environments.
Innovation Solution
Development of a chimeric antigen receptor (CAR) for γδ T cells that specifically binds to tumor-associated antigens, incorporating a binding domain, CD8α hinge, transmembrane, and costimulatory signaling regions, engineered to enhance specificity and persistence while reducing graft-versus-host responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR-T lymphocytes are engineered to enhance persistence and effector function, then tumor eradication efficacy is improved, but graft-versus-host effects are triggered
Solution Approach 1:
The patent modifies the CAR structure by changing the costimulatory domain parameter from conventional CD28 to alternative domains such as 4-1BB, OX40, or CD27. This parameter change in the costimulatory signaling pathway enables enhanced T cell persistence and tumor eradication efficacy while reducing the activation of graft-versus-host responses, thus resolving the contradiction between efficacy and safety
Solution Approach 2:
The patent introduces tissue-specific targeting by incorporating tissue-restricted serine protease (TRSP) recognition sequences into the CAR structure. This enables localized activation of the CAR only in the tumor microenvironment where TRSP is present, rather than systemic activation. The local quality change ensures that CAR-T cells exert their effector function specifically at the tumor site, improving tumor eradication while minimizing off-target graft-versus-host effects against healthy tissues
2Reliability
If γδ T cells are used for solid tumor therapy, then efficacy against solid tumors is improved, but co-stimulation requirements are unclear and safety is compromised
Solution Approach 1:
The patent applies parameter changes by modifying the CAR costimulatory domain to work specifically with γδ T cell biology. The use of 4-1BB, OX40, or CD27 costimulatory domains, which have different signaling characteristics compared to conventional CD28, creates a CAR construct that is optimized for γδ T cell activation and persistence. This parameter optimization simplifies the co-stimulation requirements for γδ T cells while maintaining safety
Solution Approach 2:
The patent incorporates TRSP recognition sequences into the CAR structure as a preliminary design feature. This preliminary action ensures that the CAR is pre-configured to be activated only in the presence of tumor-associated TRSP, providing built-in specificity for solid tumors. This preliminary structural configuration simplifies the co-stimulation requirements by adding a layer of environmental sensing that is specific to the tumor microenvironment
3Productivity
If CAR-T cells are engineered with enhanced effector function, then tumor cell killing is improved, but safety is reduced due to graft versus host effects
Solution Approach 1:
The patent implements local quality by incorporating TRSP recognition sequences into the CAR extracellular domain. This modification creates a spatially selective activation mechanism where the CAR is only activated in the tumor microenvironment that expresses TRSP, rather than being activated systemically. The local quality change ensures that high tumor cell killing activity is concentrated at the tumor site while minimizing harmful graft-versus-host effects against healthy tissues
Solution Approach 2:
The patent changes the costimulatory domain parameter to 4-1BB, OX40, or CD27, which have different signaling kinetics and magnitude compared to conventional CD28. This parameter change in the costimulatory pathway modulates the intensity and duration of T cell activation, enabling enhanced tumor cell killing while reducing the activation threshold for graft-versus-host responses, thus resolving the contradiction between productivity and safety
Data Source
AI summary
Aspects of the invention include compositions and methods for treatment of solid tumors with engineered or non-engineered γδ-T cells. In some embodiments, the γδ-T cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can contain an anti-TryD binding domain, a CD8α hinge and transmembrane domain, a costimulatory domain, a 003ζ signalling domain, a combination thereof, or all thereof. The CAR construct can contain an anti-GPC3 binding domain, a CD8α hinge and transmembrane domain, a costimulatmy domain, a CD3ζ signalling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for a secreted common gamma chain cytokine such as a sIL 15 domain.